Craig Bijou
Stock Analyst at B of A Securities
(3.78)
# 636
Out of 5,182 analysts
70
Total ratings
61.54%
Success rate
51.86%
Average return
Main Sectors:
Stocks Rated by Craig Bijou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Downgrades: Underperform | $38 → $20 | $24.52 | -18.43% | 6 | Feb 26, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Neutral | $82 → $92 | $73.20 | +25.68% | 3 | Jan 5, 2026 | |
| GMED Globus Medical | Upgrades: Buy | $65 → $91 | $92.76 | -1.90% | 5 | Nov 7, 2025 | |
| RXST RxSight | Maintains: Underperform | $18 → $9 | $7.38 | +21.95% | 2 | Jul 9, 2025 | |
| TFX Teleflex | Downgrades: Underperform | $235 → $140 | $130.22 | +7.51% | 5 | Mar 4, 2025 | |
| BLCO Bausch + Lomb | Maintains: Underperform | $18 → $17 | $16.59 | +2.47% | 3 | Feb 20, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underperform | $26 → $18 | $10.84 | +66.05% | 13 | Oct 7, 2024 | |
| ITGR Integer Holdings | Maintains: Buy | $135 → $145 | $88.37 | +64.08% | 3 | Oct 1, 2024 | |
| MMSI Merit Medical Systems | Maintains: Neutral | $92 → $103 | $70.05 | +47.04% | 3 | Sep 16, 2024 | |
| HAE Haemonetics | Initiates: Neutral | $85 | $60.11 | +41.41% | 1 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $69.38 | +36.93% | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $36 | $13.68 | +163.16% | 2 | Jan 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 → $45 | $8.64 | +420.83% | 3 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $120 | $10.40 | +1,053.85% | 2 | Mar 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $30 | $6.68 | +349.10% | 5 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8.5 → $6.5 | $15.33 | -57.60% | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $42 | $12.39 | +238.98% | 3 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $207 → $230 | $458.08 | -49.79% | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $230 | $338.38 | -32.03% | 4 | Jul 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.90 | - | 3 | Dec 4, 2017 |
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Underperform
Price Target: $38 → $20
Current: $24.52
Upside: -18.43%
GE HealthCare Technologies
Jan 5, 2026
Maintains: Neutral
Price Target: $82 → $92
Current: $73.20
Upside: +25.68%
Globus Medical
Nov 7, 2025
Upgrades: Buy
Price Target: $65 → $91
Current: $92.76
Upside: -1.90%
RxSight
Jul 9, 2025
Maintains: Underperform
Price Target: $18 → $9
Current: $7.38
Upside: +21.95%
Teleflex
Mar 4, 2025
Downgrades: Underperform
Price Target: $235 → $140
Current: $130.22
Upside: +7.51%
Bausch + Lomb
Feb 20, 2025
Maintains: Underperform
Price Target: $18 → $17
Current: $16.59
Upside: +2.47%
Integra LifeSciences Holdings
Oct 7, 2024
Maintains: Underperform
Price Target: $26 → $18
Current: $10.84
Upside: +66.05%
Integer Holdings
Oct 1, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $88.37
Upside: +64.08%
Merit Medical Systems
Sep 16, 2024
Maintains: Neutral
Price Target: $92 → $103
Current: $70.05
Upside: +47.04%
Haemonetics
Sep 11, 2024
Initiates: Neutral
Price Target: $85
Current: $60.11
Upside: +41.41%
Oct 30, 2023
Initiates: Buy
Price Target: $95
Current: $69.38
Upside: +36.93%
Jan 18, 2022
Maintains: Buy
Price Target: $43 → $36
Current: $13.68
Upside: +163.16%
May 13, 2020
Reiterates: Overweight
Price Target: $23 → $45
Current: $8.64
Upside: +420.83%
Mar 25, 2020
Maintains: Overweight
Price Target: $15 → $120
Current: $10.40
Upside: +1,053.85%
Mar 24, 2020
Maintains: Neutral
Price Target: $60 → $30
Current: $6.68
Upside: +349.10%
Mar 24, 2020
Reiterates: Overweight
Price Target: $8.5 → $6.5
Current: $15.33
Upside: -57.60%
Feb 25, 2020
Maintains: Neutral
Price Target: $48 → $42
Current: $12.39
Upside: +238.98%
Jan 10, 2020
Reiterates: Overweight
Price Target: $207 → $230
Current: $458.08
Upside: -49.79%
Jul 26, 2019
Maintains: Neutral
Price Target: $190 → $230
Current: $338.38
Upside: -32.03%
Dec 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $9.90
Upside: -